NCT00692341

Evaluation Of Hepatic Impairment On AG-013736 Pharmacokinetics

A Phase 1 Study To Evaluate The Pharmacokinetics Of AG-013736 In Subjects With Impaired Hepatic Function

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

This study will evaluate the effects of mild and moderate impairment of hepatic function on the single-dose pharmacokinetics, safety and tolerability of AG-013736.

Conditions

• Hepatic Insufficiency

Interventions

Type	Name	Description
DRUG	AG-013736	Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet.
DRUG	AG-013736	Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet.
DRUG	AG-013736	Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet.

Timeline

• Start date: 2008-05-01
• Primary completion: 2008-10-01
• Completion: 2008-10-01
• First posted: 2008-06-06
• Last updated: 2012-04-11
• Results posted: 2012-03-27

Locations

2 sites across 1 country: United States